lity for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.
Unigene Laboratories, Inc.
VP, Investor Relations and Business Administration
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
email@example.com / firstname.lastname@example.org
Page: 1 2 3 4 5 6 Related medicine technology :1
|SOURCE Unigene Laboratories, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity2
. Unigene Provides 2012 Business Outlook3
. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 94
. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist5
. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.6
. Unigene Reports Third Quarter 2011 Financial Results7
. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 20118
. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call9
. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain10
. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference11
. Cardica Announces Proposed Public Offering of Common Stock